Paradigm Biopharmaceuticals Ltd
ASX:PAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Stora Enso Oyj
OTC:SEOAY
|
FI |
|
S
|
Seven Bank Ltd
TSE:8410
|
JP |
|
S
|
Shin Shin Natural Gas Co Ltd
TWSE:9918
|
TW |
|
J
|
Jiangsu Financial Leasing Co Ltd
SSE:600901
|
CN |
|
Tekmar Group PLC
LSE:TGP
|
UK |
Paradigm Biopharmaceuticals Ltd
Other
Paradigm Biopharmaceuticals Ltd
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Other
-AU$882.3k
|
CAGR 3-Years
37%
|
CAGR 5-Years
-186%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Other
-$19.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-11%
|
|
|
CSL Ltd
ASX:CSL
|
Other
-$155m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Race Oncology Ltd
ASX:RAC
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Other
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Paradigm Biopharmaceuticals Ltd
Glance View
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.
See Also
What is Paradigm Biopharmaceuticals Ltd's Other?
Other
-882.3k
AUD
Based on the financial report for Dec 31, 2025, Paradigm Biopharmaceuticals Ltd's Other amounts to -882.3k AUD.
What is Paradigm Biopharmaceuticals Ltd's Other growth rate?
Other CAGR 5Y
-186%
Over the last year, the Other growth was 52%. The average annual Other growth rates for Paradigm Biopharmaceuticals Ltd have been 37% over the past three years , -186% over the past five years .
